Edition:
United Kingdom

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

20.56EUR
3:08pm GMT
Change (% chg)

€-0.36 (-1.72%)
Prev Close
€20.92
Open
€21.06
Day's High
€21.34
Day's Low
€20.52
Volume
96,723
Avg. Vol
135,054
52-wk High
€28.28
52-wk Low
€17.67

Latest Key Developments (Source: Significant Developments)

Genfit Cash And Cash Equivalents Up At 219.9 Million Euros At September 30
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - GENFIT SA ::REVENUES FOR FIRST NINE MONTHS OF 2018 OF EUR 68 THOUSAND.AT JUNE 30, 2018, CASH AND CASH EQUIVALENTS TOTALED €238 MILLION..AT SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS AMOUNTED TO €219.9 MILLION COMPARED WITH €113.8 MILLION ONE YEAR EARLIER..  Full Article

Genfit H1 Revenue Up At 5.1 Million Euros
Monday, 24 Sep 2018 

Sept 24 (Reuters) - GENFIT SA ::H1 OPERATING LOSS EUR 31.6 MILLION VERSUS LOSS OF EUR 22.4 MILLION YEAR AGO.H1 NET LOSS EUR 34.5 MILLION VERSUS LOSS OF EUR 22.6 MILLION YEAR AGO.H1 REVENUE EUR 5.1 MILLION VERSUS EUR 4.7 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 238 MILLION AT JUNE 30, 2018 (EUR 273.8 MILLION AT DECEMBER 31, 2017)..  Full Article

Genfit Announces Positive Elafibranor Preclinical Study Results
Wednesday, 27 Jun 2018 

June 27 (Reuters) - GENFIT SA ::NEW PRECLINICAL DATA SHOWS ELAFIBRANOR INHIBITS DEVELOPMENT OF NAFLD/NASH-RELATED CANCER.ELAFIBRANOR ADMINISTRATION PREVENTED LIVER TUMOR DEVELOPMENT IN NAFLD/NASH DISEASE MODELS.ELAFIBRANOR SHOWED DIRECT CYTOSTATIC PROPERTIES ON A LARGE SELECTION OF HUMAN TUMOR CELL-LINES.  Full Article

Genfit Announces Positive Outcome From The Safety Review By The DSMB
Monday, 23 Apr 2018 

April 23 (Reuters) - GENFIT SA ::REG-GENFIT : POSITIVE OUTCOME FROM THE 24-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.DATA SAFETY MONITORING BOARD (DSMB) WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS.POSITIVE OUTCOME, CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR.  Full Article

Genfit: Official Launch Of NASH Pediatric Program In US
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - GENFIT SA ::REG-GENFIT: OFFICIAL LAUNCH OF THE NASH PEDIATRIC PROGRAM, FOLLOWING PIP AND PSP AGREEMENT BY EMA AND FDA.‍FDA AGREES WITH ELAFIBRANOR'S INITIAL PSP FOR LAUNCH OF NASH PEDIATRIC CLINICAL TRIAL IN US.‍PHASE 2B DATA SUPPORTIVE OF ELAFIBRANOR'S POTENTIAL BENEFIT IN NASH PEDIATRIC POPULATION​.PSP AGREEMENT BY FDA CONSISTENT WITH PIP (PEDIATRIC INVESTIGATION PLAN) AGREEMENT BY EMA (EUROPEAN MEDICINES AGENCY).‍DOSE RANGING STUDY TO START IN COMING WEEKS, ON YOUNG NASH PATIENTS LIVING IN US (8-17 YEARS OLD)​.  Full Article

Genfit announces positive outcome of DSMB safety review
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.‍SAFETY DATA REVIEWED BY DSMB WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS​.‍POSITIVE OUTCOME OF REVIEW ALLOWS GENFIT TO ACTIVELY PURSUE ITS EFFORT IN ENROLLING PATIENTS AND CONTINUATION OF RESOLVE-IT TRIAL​.‍POSITIVE OUTCOME CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR​.  Full Article

Genfit completes offering of convertible bonds due 2022 for 180 million euros
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - GENFIT SA ::REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022.‍OFFERING WAS MULTIPLE TIMES OVERSCRIBED, INITIAL AMOUNT OF OFFERING WAS INCREASED FROM EUR 150 MILLION TO EUR 180 MILLION​.NOMINAL UNIT VALUE OF THE OCEANES WAS SET AT €29.60, REPRESENTING A CONVERSION/EXCHANGE PREMIUM OF 30% TO CO’S REFERENCE SHARE PRICE‍​.‍OCEANES BEAR INTEREST AT AN ANNUAL NOMINAL RATE OF 3.50% PAYABLE SEMI-ANNUALLY IN ARREARS ON APRIL 16, AND OCT 16 OF EACH YEAR​.  Full Article

Genfit completes convertible bonds offering for amount of 180 million euros
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - GENFIT SA ::REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION.‍INITIAL AMOUNT OF EUR 150 MILLION HAS BEEN INCREASED TO EUR 180 MILLION IN ACCORDANCE WITH CORPORATE AUTHORIZATIONS OF COMPANY​.  Full Article

Genfit launches an offering of conbertible bonds for around 150 million euros
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - GENFIT SA ::GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION.‍OCEANES WILL BEAR INTEREST AT AN ANNUAL NOMINAL RATE COMPRISED BETWEEN 3.00% AND 3.50% PAYABLE SEMI-ANNUALLY​.‍NOMINAL UNIT VALUE OF OCEANES WILL BE SET AT A CONVERSION/EXCHANGE PREMIUM OF BETWEEN 30% AND 35% TO GENFIT'S REFERENCE SHARE PRICE​.BONDS TO BE REDEEMED AT PAR ON OCT 16, 2022.‍​.  Full Article

Genfit reports‍ nine months revenues at 91 thousand euros
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - GENFIT SA : :‍CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017​.‍REVENUES FOR FIRST NINE MONTHS OF 2017 OF EUR 91 THOUSAND​.  Full Article

Photo

Novartis, Pfizer join forces on potentially lucrative fatty liver disease

ZURICH/NEW YORK Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.